TripleTree Drives Healthcare M&A Buzz with Latest Acquisitions
Deal News | Jun 10, 2025 | TT Capital Partners LLC
This week's edition of TripleTree's Healthcare M&A Weekly provides an overview of significant mergers and acquisitions shaping the future of the healthcare industry. Highlighted transactions include Allay Therapeutics completing a $57.5 million Series D financing round co-led by Lightstone Ventures and ClavystBio. Avista Healthcare Partners acquired the bone healing division of Highridge Medical, while Carlyle and SK Capital Partners facilitated the sale of bluebird bio. Noteworthy deals include acquisitions by Clearview Capital, ENT Partners, Guardian Pharmacy Services, H1, Juvenescence Limited, Lucet, Net Health, Pyx Health, Quantum Health, RadNet, Sanofi, and Valera Health. These transactions illustrate the dynamic evolution of the healthcare sector, marked by innovation and strategic investments.
Sectors
- Healthcare
- Biotechnology
- Pharmaceuticals
- Private Equity
Geography
- United States – Many of the companies involved, such as Guardian Pharmacy Services and ENT Partners, are based in the U.S., reflecting significant domestic activity.
- Global – Companies like RadNet's DeepHealth and See-Mode Technologies highlight the global span of M&A activities in the healthcare sector.
Industry
- Healthcare – The article discusses multiple transactions involving companies in the healthcare industry, highlighting trends in healthcare technology and services.
- Biotechnology – Allay Therapeutics and Juvenescence Limited illustrate key activities in the biotech sector, focusing on clinical-stage developments and AI-enhanced drug discovery.
- Pharmaceuticals – The acquisition of Blueprint Medicines by Sanofi showcases significant movements within the pharmaceutical industry.
- Private Equity – The involvement of TT Capital Partners and other private equity firms in multiple transactions indicates a strong investment interest in the healthcare industry.
Financials
- $57.5M – Series D financing round completed by Allay Therapeutics.
- $47.5M – Investment by S2G Investments to support Pyx Health's acquisition of FarmboxRx.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TT Capital Partners | Investor | Company | TT Capital Partners, a prominent private equity firm, backed the Pyx Health acquisition deal. |
| Allay Therapeutics | Target Company | Company | A biotechnology company that completed a $57.5M Series D financing round. |
| Lightstone Ventures | Investor | Company | Co-led the Series D financing for Allay Therapeutics. |
| ClavystBio | Investor | Company | Co-led the Series D financing for Allay Therapeutics. |
| Avista Healthcare Partners | Buyer | Company | Acquisition of EBI, the bone healing division of Highridge Medical. |
| bluebird bio | Target Company | Company | Sold to funds managed by Carlyle and SK Capital Partners. |
| Carlyle | Buyer | Company | Global investment firm involved in the acquisition of bluebird bio. |
| SK Capital Partners | Buyer | Company | Global investment firm involved in the acquisition of bluebird bio. |
| Clearview Capital | Buyer | Company | Acquired Outpatient Imaging for its portfolio company Capitol Imaging Services. |
| Sanofi | Buyer | Company | Agreed to acquire Blueprint Medicines Corporation. |